Synthesis and pharmacological evaluation of new4-[2-(7-heterocyclemethoxynaftalen-2-ylmethoxy)ethyl]benzoic acidsas LTD4-antagonists

doi:10.1016/S0223-5234(00)00142-2

Paper

Synthesis and pharmacological evaluation of new4-[2-(7-heterocyclemethoxynaftalen-2-ylmethoxy)ethyl]benzoic acidsas LTD4-antagonists

Published Apr 1, 2000 · B. Ballart

European Journal of Medicinal Chemistry

Q2 SJR score

1

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Study Snapshot

New 4-[2-(7-heterocyclemethoxynaftalen-2-ylmethoxy)ethyl]benzoic acids show considerable activity and improved pharmacokinetic profiles as LTD4-antagonists, highlighting their potential as oral antiasthmatics.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Paper

Synthesis and pharmacological evaluation of new4-[2-(7-heterocyclemethoxynaftalen-2-ylmethoxy)ethyl]benzoic acidsas LTD4-antagonists

References

Development of a three-dimensional CysLT1 (LTD4) antagonist model with an incorporated amino acid residue from the receptor.

The developed molecular model of CysLT1 antagonists reveals additional interactions between guanidine groups and nitrogen atoms, potentially improving understanding of receptor recognition.

Synthesis and pharmacological evaluation of new cysLT1 receptor antagonists

New cysLT1 receptor antagonists with potency at nanomolar concentrations were synthesized and evaluated.

Synthesis of structural analogs of leukotriene B4 and their receptor binding activity.

Structural analogs of leukotriene B4 show improved receptor binding and antagonist activity, with 47 showing antagonist activity.

Leukotriene-Receptor Antagonists and 5-Lipoxygenase Inhibitors in Asthma

Recent clinical trials using leukotriene-receptor antagonists and 5-lipoxygenase inhibitors show promising results for expanding asthma therapeutic regimens.

Peptidoleukotriene Antagonists State of the Art

Peptidoleukotriene antagonists show promise as a new asthma therapy, with new classes showing promising results in clinical trials.

Evolution of a series of peptidoleukotriene antagonists: synthesis and structure/activity relationships of 1,3,5-substituted indoles and indazoles.

1,3,5-substituted indoles and indazoles show potential as peptidoleukotriene antagonists, with compounds like 45 showing potential for asthma treatment.

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

This rapid and sensitive protein determination method uses Coomassie Brilliant Blue G-250 binding to protein, resulting in a shift in absorption maximum and good color stability for 1 hour.

Citations